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Abstract
Background
Interventional diagnostic and therapeutic procedures requiring intravascular iodinated con-
trast steadily increase patient exposure to the risks of contrast-induced acute kidney injury
(CIAKI), which is associated with death, nonfatal cardiovascular events, and prolonged hos-
pitalization. The aim of this study was to investigate the efficacy of pharmacological and
non-pharmacological treatments for CIAKI prevention in patients undergoing cardiovascular
invasive procedures with iodinated contrast.
Methods and findings
MEDLINE, Google Scholar, EMBASE and Cochrane databases as well as abstracts and
presentations from major cardiovascular and nephrology meetings were searched, up to 22
April 2016. Eligible studies were randomized trials comparing strategies to prevent CIAKI
(alone or in combination) when added to saline versus each other, saline, placebo, or no
treatment in patients undergoing cardiovascular invasive procedures with administration
of iodinated contrast. Two reviewers independently extracted trial-level data including num-
ber of patients, duration of follow-up, and outcomes. Eighteen strategies aimed at CIAKI
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prevention were identified. The primary outcome was the occurrence of CIAKI. Secondary
outcomes were mortality, myocardial infarction, dialysis and heart failure. The data were
pooled using network meta-analysis. Treatment estimates were calculated as odds ratios
(ORs) with 95% credible intervals (CrI). 147 RCTs involving 33,463 patients were eligible.
Saline plus N-acetylcysteine (OR 0.72, 95%CrI 0.57–0.88), ascorbic acid (0.59, 0.34–0.95),
sodium bicarbonate plus N-acetylcysteine (0.59, 0.36–0.89), probucol (0.42, 0.15–0.91),
methylxanthines (0.39, 0.20–0.66), statin (0.36, 0.21–0.59), device-guided matched hydra-
tion (0.35, 0.12–0.79), prostaglandins (0.26, 0.08–0.62) and trimetazidine (0.26, 0.09–0.59)
were associated with lower odds of CIAKI compared to saline. Methylxanthines (0.12, 0.01–
0.94) or left ventricular end-diastolic pressure-guided hydration (0.09, 0.01–0.59) were
associated with lower mortality compared to saline.
Conclusions
Currently recommended treatment with saline as the only measure to prevent CIAKI during
cardiovascular procedures may not represent the optimal strategy. Vasodilators, when
added to saline, may significantly reduce the odds of CIAKI following cardiovascular
procedures.
Introduction
Interventional diagnostic and therapeutic procedures requiring intravascular iodinated con-
trast are performed in millions of patients worldwide and are steadily increasing patient expo-
sure to the risks of contrast-induced acute kidney injury (CIAKI)[1]. As CIAKI is associated
with death, nonfatal cardiovascular events, and prolonged hospitalization[2], the adoption of
optimal therapeutic strategies to prevent this complication offers an opportunity to reduce
patient morbidity and mortality. International guidelines advocate hydration as the standard
therapeutic strategy to minimise CIAKI, with lower levels of recommendation assigned to
other preventive strategies, given limited evidence from individual studies[3–5]. Although
there are numerous candidate therapies to prevent CIAKI, individual head-to-head trials and
pairwise meta-analyses cannot simultaneously compare all the available treatments tested in
the periprocedural period.
We therefore performed a network meta-analysis of pharmacological and non-pharmaco-
logical treatments assessed in randomised controlled trials (RCTs) for the prevention of
CIAKI in patients undergoing cardiovascular invasive procedures with iodinated contrast.
Methods
We registered the study protocol with PROSPERO (CRD42015016488) and conducted and
reported this review using the Preferred Reporting Items for Systematic Reviews and Meta-
analyses (PRISMA) extension statement for reporting systematic reviews incorporating net-
work meta-analyses of health care interventions (S1 File)[6].
Data source and search strategy
We searched electronic databases (MEDLINE, Cochrane Central Register of Controlled Trials
(CENTRAL), Google Scholar and EMBASE) and the websites www.clinicaltrials.gov, www.
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clinicaltrialresults.org, as well as proceedings of major cardiovascular and nephrology societies
(American Society of Nephrology, European Dialysis and Transplant Association, World Con-
gress of Nephrology, European Society of Cardiology, American College of Cardiology, and
American Heart Association), up to 22 April 2016. We used the following search terms: rando-
mised controlled trial, contrast-induced acute kidney injury, contrast-induced nephropathy,
acute renal failure, contrast renal failure, contrast nephropathy, acetylcysteine, N-acetylcysteine,
aminophylline, ascorbic acid, vitamin C, atrial natriuretic peptide (ANP), brain natriuretic pep-
tide (BNP), fenoldopam, furosemide, haemodialysis, haemofiltration, renal replacement ther-
apy, iloprost, prostaglandin E1 (PGE-1), mannitol, nebivolol, probucol, matched hydration,
RenalGuard1, saline, 0.9% NaCl, statin, HMG-CoA reductase inhibitor, sodium bicarbonate,
theophylline, trimetazidine, and left ventricular end-diastolic pressure (LVEDP)-guided hydra-
tion. The MEDLINE search strategy is provided in Table A in S1 Appendix.
Selection criteria
We screened the title and abstract of all retrieved records for eligibility according to the study
protocol. We applied no restrictions on language or publication status during this assessment.
We then reviewed in full text all citations that appeared relevant to determine inclusion in the
systematic review. We included RCTs comparing strategies to prevent CIAKI (alone or in com-
bination) when added to saline versus each other, saline, placebo, or no treatment in patients
undergoing cardiovascular invasive procedures with administration of iodinated contrast. We
excluded non-randomised studies, studies in the setting of computed tomography alone, studies
in which the number of events for the clinical outcome of interest was not reported, studies in
which the evidence on a treatment was limited to one RCT with fewer than 100 patients, studies
testing early-stage investigational strategies, and studies comparing the same drug at different
doses without other control groups.
Data extraction, synthesis and quality assessment
Data were independently abstracted by three investigators (TJ, MJ and VG) on prespecified
forms. Differences were resolved by consensus after discussion with a fourth investigator
(MK). Study risk of bias was assessed using Cochrane Collaboration criteria[7].
Study endpoints
The primary endpoint was CIAKI as defined in the protocol of the original RCT. If multiple
definitions of CIAKI were reported, the trial’s primary endpoint definition was applied. As a
prespecified analysis, CIAKI in subsets of patients with moderate or severe kidney disease at
baseline was assessed. We included mortality, myocardial infarction, need for dialysis, and
heart failure as secondary outcomes.
Statistical analyses
Network meta-analyses compare different treatments within a connected analytical network
[8], integrating data from direct and indirect treatment comparisons whilst maintaining the
randomisation design[9]. We used a Bayesian hierarchical random-effects model, which is the
most conservative and accounts for differences among trials[10,11]. Comparative treatment
estimates were calculated as odds ratios (ORs) with 95% credible intervals (CrI). Results for
which the 95% CrI of the OR did not include unity were considered significant and are pre-
sented in bold in the outcome tables.
Network meta-analysis for prevention of CIAKI
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Model fit was assessed by comparing the posterior mean of the residual deviance to the
number of data points[12,13]. We investigated the extent of heterogeneity in each network by
examining the magnitude of the common heterogeneity variance τau2 for the network[14].
We applied a standard 0.5 zero-cell correction when there were zero events in one arm of the
trial. Studies in which all arms had zero events were excluded as not providing evidence of rel-
ative treatment effects.
The network meta-analysis approach assumes consistency, i.e., that one can learn about
treatment A versus treatment B through a common comparator, treatment C. We assumed
that, in principle, participants in studies fulfilling our inclusion criteria could be randomly
allocated to any of the treatments being compared. We evaluated evidence of inconsistency in
the network, defined as difference in treatment estimates derived from direct and indirect
treatment comparisons, using the node splitting method and the corresponding Bayesian p-
value, which determines the statistical agreement between direct and indirect evidence for
each split node[15]. This was implemented using the gemtc R package[16].
We also explored potential sources of statistical heterogeneity and inconsistency through sub-
group analyses and univariate random-effects meta-regression[7]. To this end, we stratified stud-
ies according to baseline estimated glomerular filtration rate (eGFR), as either 30–59 mL/min
per 1.73 m2 (moderate chronic kidney disease [CKD]), or<30 mL/min per 1.73 m2 (severe
CKD) according to KDOQI stages of CKD[17]. We additionally performed meta-regression
analyses, considering baseline mean age and diabetes as effect modifiers on estimates for CIAKI.
Calculation of the probability that each treatment is the best was performed by counting the
proportion of iterations in the Monte Carlo simulation at which each treatment had the most
favourable outcome. We also estimated the relative ranking probability of each treatment and
obtained the treatment hierarchy of competing interventions using rankograms. To obtain the
absolute probabilities of events for all treatments, a reference study[18] was chosen to provide
the probability of events for the reference treatment onto which the odds ratios were applied
(on the log-odds scale) to obtain the absolute probabilities of events for all treatments[19].
These were then used to calculate the numbers needed to treat (NNT) or to harm (NNH) to
prevent or cause one event for the compared treatments[13,20].
In additional prespecified sensitivity analyses we excluded studies in which<100 mL of
contrast medium was administered for assumed low complexity of the procedure, or studies
that did not define CIAKI as a25% relative or0.5 mg/dL (44 μmol/L) absolute increase
in serum creatinine from baseline within 48–72 hours after contrast exposure. We explored
potential publication bias by constructing funnel plots for the clinical outcomes in which the
standard error of the log of the OR was plotted against the OR[7]. The network meta-analysis
models used noninformative prior distributions for effect sizes (Normal(0,1002)) and
between-studies standard deviation (Uniform(0,2)), which yield comparable results to those
obtained by conventional statistical analysis. Models were estimated using Markov Chain
Monte Carlo implemented inWinBUGS 1.4.3. Convergence was achieved at 20,000 iterations
for all outcomes and lack of autocorrelation was checked and confirmed.
We conducted the analyses in WinBugs version 1.4.3 (MRC Biostatistics Unit, Cambridge,
UK) and R version 3.1.4 (R Development Core Team, Vienna, Austria).
Results
Study selection and characteristics
A total of 33,463 patients from 147 studies were eligible for inclusion (Table B in S1 Appendix).
The PRISMA flowchart showing the electronic search process is available as Fig 1. Eighteen treat-
ments, including saline (reference treatment), saline plus N-acetylcysteine, sodium bicarbonate,
Network meta-analysis for prevention of CIAKI
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sodium bicarbonate plus N-acetylcysteine, ascorbic acid, statins, furosemide, probucol, methyl-
xanthines, fenoldopam, device-guided matched hydration, renal replacement therapy, nebivolol,
Fig 1. Flow diagram of network meta-analysis.
doi:10.1371/journal.pone.0168726.g001
Network meta-analysis for prevention of CIAKI
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natriuretic peptides, mannitol, prostaglandins, trimetazidine and LVEDP-guided hydration, were
compared (Fig 2). The large majority of cardiovascular invasive procedures were coronary angi-
ographies with or without percutaneous coronary intervention. The study mean age of partici-
pants was 65.0 years (Table C in S1 Appendix). On average, 142.80 mL of contrast agent per
procedure was administered (Table D in S1 Appendix). The number of patients and events for
single pairwise comparisons are shown in Table E in S1 Appendix.
Risk of bias
The risk of bias in studies contributing to the primary outcome is shown in Fig A in S1 Appen-
dix. The large majority of studies showed low risk of bias in random sequence generation and
in incomplete outcome reporting. Several studies were open-label.
Fig 2. Network of treatment comparisons for prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular invasive
procedures. The size of the nodes corresponds to the number of trials that studied the treatments. Directly compared treatments are linked with a line, the
thickness of which corresponds to the number of trials that assessed the comparison. LVEDP = left ventricular end-diastolic pressure; NAC = N-acetyl
cysteine; n = number of patients allocated to a specific treatment.
doi:10.1371/journal.pone.0168726.g002
Network meta-analysis for prevention of CIAKI
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Network consistency
There was no evidence of inconsistency between direct and indirect estimates for the com-
pared drug treatments in CIAKI, with non-significant Bayesian p-values for the comparisons
(Table F in S1 Appendix). Visual inspection of funnel plots did not suggest any small study
effects (Figure B A-E in S1 Appendix). Evaluation of the goodness of fit of the models showed
adequate fit for all outcomes (Table G in S1 Appendix). Heterogeneity among trials was mod-
erate for CIAKI, mortality and heart failure, whereas it was substantial for need for dialysis
and myocardial infarction (Table G in S1 Appendix).
Primary endpoint: CIAKI
All 147 studies (n = 33,463) contributed to the network analysis for the primary endpoint of
CIAKI (Fig 2). Several interventions were associated with lower odds of CIAKI compared with
saline treatment (Fig 3). Saline plus N-acetyl cysteine (OR 0.72, 95% CrI 0.57–0.88), ascorbic
acid (0.59, 0.34–0.95), sodium bicarbonate plus N-acetyl cysteine (0.59, 0.36–0.89), probucol
(0.42, 0.15–0.91), methylxanthines (0.39, 0.20–0.66), statin (0.36, 0.21–0.59), device-guided
matched hydration (0.35, 0.12–0.79), prostaglandins (0.26, 0.08–0.62) and trimetazidine (0.26,
0.09–0.59) were associated with lower odds of CIAKI compared to saline. Prostaglandin, tri-
metazidine, methylxanthine or statin therapy was associated with lower odds of CIAKI com-
pared with saline plus N-acetyl cysteine. Table 1 summarises the probability that each
treatment is the best compared to saline (reference treatment): there was a 31.03% probability
that prostaglandins had the lowest CIAKI rate, followed by trimetazidine (27.38%) and
Fig 3. Network meta-analysis odds ratios and 95% credible intervals for contrast-induced acute kidney injury. Comparisons between treatments
should be read from left to right. Estimates of treatment effects in the cell in common between the row-defining treatment and the column-defining treatment.
Odds ratios lower than 1 favour the row-defining treatment. To obtain odds ratios for comparisons in the opposite direction, reciprocals should be taken.
Significant results are in bold and underlined. ER = event rate; LVEDP = left ventricular end-diastolic pressure; NAC = N-acetylcysteine.
doi:10.1371/journal.pone.0168726.g003
Network meta-analysis for prevention of CIAKI
PLOS ONE | DOI:10.1371/journal.pone.0168726 February 2, 2017 7 / 15
LVEDP-guided hydration (14.37%). Rankograms for the competing treatments are shown in
Fig C in S1 Appendix.
Secondary outcomes
Thirty-eight studies (involving 14,372 patients) contributed to the network for mortality (Fig
D in S1 Appendix). Compared with saline, methylxanthines (0.12, 0.01–0.94) and LVEDP-
guided hydration (0.09, 0.01–0.59) were associated with lower odds of death in the overall
analysis (Fig 4, Table G in S1 Appendix). Data on the need for dialysis were derived from 43
studies (involving 14,985 patients). There were significantly lower odds of need for dialysis
with device-guided matched hydration (0.05, 0.01–0.58). Myocardial infarction and heart fail-
ure data were available in 12 (n = 2,900) and 17 studies (n = 6,284), respectively. Among com-
pared treatments, LVEDP-guided hydration was associated with lower odds of myocardial
infarction compared to saline (0.27, 0.07–0.80). There was no evidence of significantly differ-
ent effects on heart failure among treatments.
Sensitivity and subgroup analyses
Kidney function. Sixty-nine studies (involving 12,934 patients) contributed to the analy-
sis of CIAKI restricted to patients with moderate CKD. Among these patients, prostaglandins
and trimetazidine were associated with lower odds of CIAKI when compared to either saline
or saline plus N-acetyl-cysteine (Fig E in S1 Appendix); saline plus N-acetylcysteine was supe-
rior to saline alone. Renal replacement therapy was associated with increased odds of CIAKI
Table 1. Overall and GFR stratified analysis for CIAKI prevention, with NNT.
Treatment Overall analysis GFR 59–30 ml/min GFR 30 ml/min
Probability to be the best
[%]
NNT Probability to be the best
[%]
NNT Probability to be the best
[%]
NNT
Saline - - - - - -
Saline plus N-acetylcysteine 0.0 30.79 0.0 33.90 16.99 5.35
Sodium bicarbonate 0.0 32.61 0.0 35.74 na na
Sodium bicarbonate plus N-acetyl
cysteine
0.006 20.22 0.001 24.89 na na
Ascorbic acid 0.03 19.97 0.004 25.63 na na
Statin 1.53 13.07 1.14 14.57 na na
Furosemide 0.0 -14.29 0.13 -5.35 0.73 -3.51
Probucol 5.24 13.48 na na na na
Methylxanthines 2.17 13.48 3.66 14.10 na na
Fenoldopam 0.01 14.81 0.02 -9.52 1.64 -2.31
Device-guided matched hydration 12.45 12.15 11.74 11.62 na na
Renal replacement therapy 0.14 19.74 0.002 -5.61 62.40 4.72
Nebivolol 0.94 14.81 1.93 13.97 na na
Natriuretic peptides 3.22 14.84 0.78 -3.93 18.24 5.49
Mannitol 1.13 13.52 8.22 10.71 na na
Prostaglandins 31.03 10.87 35.63 10.24 na na
Trimetazidine 27.38 10.97 33.24 10.43 na na
LVEDP-guided hydration 14.37 12.21 3.51 13.43 na na
CIAKI = contrast-induced acute kidney injury. GFR = glomerular filtration rate; na = not available; NNT = number needed to treat to prevent one episode of
CIAKI.
doi:10.1371/journal.pone.0168726.t001
Network meta-analysis for prevention of CIAKI
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when compared to saline plus N-acetylcysteine, statin, device-guided matched hydration,
prostaglandins, trimetazidine and LVEDP-guided hydration. Nine studies (involving 1,205
patients) contributed to the analysis of CIAKI in patients with severe CKD: in these patients,
renal replacement therapy and saline plus N-acetylcysteine were associated with lower odds of
CIAKI when compared to saline (Fig F in S1 Appendix). Renal replacement therapy was asso-
ciated with lower odds of death among severe CKD patients (0.21, 0.09–0.46) compared to
saline (Fig 4).
Contrast volume. Among patients receiving>100 mL of contrast, the lowest odds of
CIAKI were found with prostaglandins (0.26, 0.08–0.62), trimetazidine (0.26, 0.07–0.66),
methylxanthines (0.27, 0.11–0.53) and device-guided matched hydration (0.33, 0.11–0.76)
compared to saline (Fig G in S1 Appendix).
Stringent definition of CIAKI. In studies that defined CIAKI as a25% relative, or
0.5 mg/dL or44 μmol/L absolute, increase in serum creatinine from baseline within
Fig 4. Forest plots for effect sizes of treatment strategies compared with saline, for mortality, dialysis, myocardial infarction and heart failure.
Estimates are presented as odds ratios and 95% credible intervals (95% CrI). LVEDP = left ventricular end-diastolic pressure; NAC = N-acetylcysteine; *in
severe chronic kidney disease.
doi:10.1371/journal.pone.0168726.g004
Network meta-analysis for prevention of CIAKI
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48–72 hours after contrast exposure, the results were consistent with the main analyses (Fig
H in S1 Appendix). The greatest CIAKI odds reductions were observed with trimetazidine
(0.21, 0.05 to 0.75), prostaglandins (0.23, 0.09 to 0.56), probucol (0.27, 0.09 to 0.79) and
statin (0.30, 0.16 to 0.52) as compared to saline. Similar results were observed when these
treatments were compared to the combination of saline plus N-acetylcysteine.
Meta-regression. Meta-regression analysis showed that neither baseline prevalence of dia-
betes (beta: -0.25 [-0.61 to 0.10]) nor mean age (beta: -0.02 [-0.05 to 0.02]) influenced the over-
all results.
Discussion
Cardiovascular invasive procedures with contrast media are increasingly performed in routine
clinical practice. Contrast-induced acute kidney injury (CIAKI) is a leading cause of hospital-
acquired renal failure, associated in turn with a stepwise increase of mortality and a relevant
impact on public health[2]. The present report is the largest database ever analysed on different
treatments to prevent CIAKI in the setting of cardiovascular invasive procedures.
The main findings of this network meta-analysis, including 147 RCTs and 33,463 patients,
are that methylxanthines, prostaglandins and trimetazidine resulted in the lowest odds of CIAKI
as compared to saline or to saline plus N-acetylcysteine following cardiovascular invasive proce-
dures requiring iodinated contrast. When compared to saline alone, methylxanthines, renal
replacement therapy limited to severe kidney disease patients, and LVEDP-guided hydration
were associated with lower odds of mortality, while LVEDP-guided hydration was also associ-
ated with reduced odds of myocardial infarction.
European Society of Cardiology guidelines recommend hydration to prevent CIAKI in
addition to limited contrast volume and to the use of iso- or low- osmolar contrast agents[5].
Similarly, the KDIGO Clinical Practice Guideline for Acute Kidney Injury recommends vol-
ume expansion with either isotonic sodium chloride or sodium bicarbonate in patients at high
risk of CIAKI[4,21]. To date, however, no robust conclusions on the comparative efficacy of
all potential preventive measures against CIAKI could be drawn, given the small numbers of
patients enrolled in the single studies and the limited treatment group comparisons. As a con-
sequence, preventive measures other than saline have been discouraged by international guide-
lines. The limited available trial evidence is reflected by variations in routine clinical practice.
Current practice indicates that prevention of CIAKI with saline or saline plus N-acetylcysteine
provides only limited efficacy, leaving the physician ultimately challenged by the choice of
other treatment options[22].
A key finding of this network meta-analysis is the significantly lower odds of CIAKI with
added-on vasodilator agents, namely methylxanthines, prostaglandins, and trimetazidine,
compared to recommended standard treatments such as saline or saline plus N-acetylcysteine
alone. This benefit persisted in the analyses stratified by baseline kidney function.
The pathophysiological basis for the present findings includes the reduction in renal perfu-
sion and the toxic effect on tubular cells induced by contrast media that are generally recognised
as important determinants of CIAKI[23]. This network meta-analysis challenges current inter-
national guidelines by demonstrating that effective prevention of CIAKI may not be optimally
achieved with saline hydration alone. The addition of other agents, particularly vasodilators
such as prostaglandins, methylxanthines and trimetazidine, has the potential to significantly
reduce the occurrence of CIAKI and other patient-relevant endpoints, and warrants evaluation
in large randomised trials. The complete biological mechanism underlying the effectiveness of
vasodilator agents is not entirely clarified, and may include beneficial effects on cardiac function
and haemodynamic performance.
Network meta-analysis for prevention of CIAKI
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In this network meta-analysis, the benefits of vasodilator agents assumed a particular distri-
bution in patients with different baseline renal function. The protective effects of prostaglan-
dins were evident in the main analysis and persisted in the sensitivity analyses of patients who
had moderate CKD, studies in which a stringent CIAKI definition was used, and studies in
which>100 mL contrast volume was administered. In response to ischaemia, the synthesis of
prostaglandins is normally increased to modulate renal vascular resistance with a predomi-
nance of vasodilatory PGI2 and PGE2, in contrast to vasoconstricting PGF2 and thromboxane
[24]. In the presence of CKD, the release of eicosanoids, predominantly PGE2, is impaired
[25]. Therefore, it is biologically plausible that the external administration of prostaglandins
might abrogate renal hypoxia that is indeed increased in more advanced stages of kidney dys-
function. The association of methylxanthines with lower odds of CIAKI, observed in the main
analysis, was present but less pronounced in moderate stages of CKD. These results might be
explained by the fact that methylxanthines affect renal haemodynamics by blocking compensa-
tory adenosine-mediated vasoconstriction in the early stages of CKD [25,26]. This effect can
be less pronounced in more advanced stages of renal dysfunction, owing to increased renal
hypoxia and reduced synthesis of nitric oxide and adenosine.
Our findings that vasodilator agents can be beneficial are concordant with single pairwise
meta-analyses showing that methylxanthines and trimetazidine reduce the incidence of CIAKI
[27,28]. This large-scale network meta-analysis, however, substantially differs from the single
pairwise meta-analyses by providing unified hierarchies of evidence for the several available
treatments to prevent CIAKI. In this meta-analysis a significant benefit was observed with
LVEDP-guided hydration on the clinical outcomes of death and myocardial infarction. Multi-
ple reasons may explain this finding including plasma volume expansion, reduced renin acti-
vation, reduced loss of nitric oxide, reduced concentrations of reactive oxygen species, as well
as higher dilution of contrast within the tubular lumen[29,30], although in our paper the mag-
nitude of CIAKI reduction with this strategy was only numerical and not significant in com-
parison with other treatments, partly because the available evidence was limited to a single
RCT.
Notably, in our network meta-analysis, renal replacement therapy exerted a possible GFR-
dependent effect on CIAKI prevention compared to saline hydration, with signals of potential
harm in patients with moderate CKD in contrast to lower odds of CIAKI among patients with
severe CKD. The directionally opposite biological effects of renal replacement therapy in mod-
erate and severe kidney dysfunction may have contributed at least in part to some heterogeneity
in the network for the main CIAKI endpoint. The underlying mechanisms leading to harmful
effects of renal replacement therapy are possibly multiple; hypotension and myocardial stun-
ning may correlate with loss of residual renal function[31,32]; blood contact with the dialysis
membrane may promote a pro-inflammatory systemic response which may in itself lead to
accelerated kidney injury; as a result, renal replacement therapy should be considered only in
severe CKD patients[33,34], who are most predisposed to develop CIAKI, and in whom the
benefits of renal replacement therapy would be expected to outnumber the risks. Our current
findings on the favorable effects of vasodilator treatment strategies are in line with results
observed in recent network meta-analysis[35]. At variance with the previous meta-analysis
focused on drug treatments only and with no inference on other outcomes than CIAKI [35], we
extended the analysis to both drug and invasive treatments to prevent CIAKI as LVDEP-guided
hydration that in our present paper has been proven to improve significantly survival. More-
over, in the paper by Su et al statin therapy was divided in high and low doses based on a non
declared statin type and dose classification strategy, an operation that prompts caution when
interpreting results on high dose statin therapy referred as a potential best strategyOur network
meta-analysis has limitations that need to be considered when interpreting its findings. The
Network meta-analysis for prevention of CIAKI
PLOS ONE | DOI:10.1371/journal.pone.0168726 February 2, 2017 11 / 15
results were analysed on trial level data and not on individual patient data. Not all trials
assessed or reported GFR or CIAKI by the same method or definition; however, sensitivity
analyses for different stages of CKD and using a stringent definition of CIAKI indicated stable
results. Moderate to significant heterogeneity was found in the networks for most endpoints.
A certain degree of heterogeneity is inevitable when integrating the large body of available
RCT evidence on CIAKI. We explored potential sources of heterogeneity and found no evi-
dence in meta-regression analyses that prespecified study-level variables such as age and prev-
alence of diabetes impacted the results. We also noted no statistically significant differences in
treatment estimates from direct and indirect drug treatment comparisons, indicating that the
assumption of transitivity, necessary for network analyses, was appropriate. Although the
power of consistency checks is limited when direct comparisons are few, the non-significant
Bayesian p-values describing the probability that the direct and indirect evidence differ, cor-
roborate the a priori assumptions of transitivity. Some heterogeneity for the main CIAKI end-
point is likely explained by the directionally opposite treatment effect of renal replacement
therapy in moderate versus severe CKD patients; however, other sources of unexplained het-
erogeneity cannot be excluded. Several studies presented design limitations including the
small sample size and the fact that some of them were single center RCTs; however the present
network meta-analysis by design addresses the small sample size in single studies by providing
a large-scale analysis and more precise estimates. this network although is the largest source
of evidence does not include several treatment agents such as sodium/potassium citrate, allo-
purinol for which however exists large uncertainty as measures to prevent CIAKI; a stratified
analysis based on different statin doses was not performed given the substantial variations in
doses and types used across different trials. Caution should be exerted when referring to the
LVEDP-guided hydration findings given the single trial available so far. Given the association
of LVEDP-guided therapy with lower CIAKI and mortality, further studies are needed to
assess the LVEDP-guided strategy. Clinical endpoints other than CIAKI were analysed in a
minority of studies and individual RCTs were underpowered for the assessment of mortality.
Thus, these endpoint data should be viewed as preliminary, requiring formal testing in large
RCTs. The potential harms and costs for the considered treatments were not explored.
Conclusion
The results of the present network meta-analysis support the notion that treatment with saline
during cardiovascular invasive procedures may not represent the optimal strategy to prevent
CIAKI. Large specific RCTs aimed at enhancing CIAKI prevention are warranted, as the find-
ings, if confirmed, would have a profound impact on public health.
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